Theriva Biologics, Inc. (TOVX) Financial Statements

Theriva Biologics, Inc. (TOVX) files with the U.S. Securities and Exchange Commission under CIK 0000894158. 10KGenie shows its annual and quarterly statements from SEC filings.

Key Figures, Fiscal Year 2025

Total Assets
$38.24 million
Net Cash from Operations
-$16.67 million

Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Aug 11, 2026. Source: SEC filings (EDGAR XBRL).

Open the full financial statements for TOVX in 10KGenie

Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History